HRP20180192T1 - Liječenje tumora specifičnim protutijelom protiv l1 - Google Patents

Liječenje tumora specifičnim protutijelom protiv l1 Download PDF

Info

Publication number
HRP20180192T1
HRP20180192T1 HRP20180192TT HRP20180192T HRP20180192T1 HR P20180192 T1 HRP20180192 T1 HR P20180192T1 HR P20180192T T HRP20180192T T HR P20180192TT HR P20180192 T HRP20180192 T HR P20180192T HR P20180192 T1 HRP20180192 T1 HR P20180192T1
Authority
HR
Croatia
Prior art keywords
binding molecule
binding
seq
intended
cancer
Prior art date
Application number
HRP20180192TT
Other languages
English (en)
Inventor
Daniela Kelm
Peter Altevogt
Sandra Lüttgau
Achim Krüger
Gerhard Moldenhauer
Frank Breitling
Silke Bärreiter
Yi Li
Ulrich Möbius
Susanne Sebens
Heiner Schäfer
Original Assignee
Medigene Ag
Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigene Ag, Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts filed Critical Medigene Ag
Publication of HRP20180192T1 publication Critical patent/HRP20180192T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/02—Radiation therapy using microwaves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)

Claims (16)

1. Vežuća molekula koja se može vezati na L1, (a) koja se bira iz skupine koju čine jednolančana protutijela, scFv, multimeri scFv, poput diatijela, triatijela ili tetratijela, fragmenti protutijela, Fab, tandabs, fleksitijela, bispecifična protutijela, te kimerna protutijela, i/ili (b) koja sadrže najmanje jednu Ig domenu, te naznačena time što je za vežuću molekulu koja se može vezati na L1: (i) karakteristično da njezina područja koja određuju komplementarnost (CDR) imaju sljedeće sljedove: LCDR1: RASQDISNYLN (SEQ ID No.: 24), LCDR2: YTSRLHS (SEQ ID No.: 25), LCDR3: QQGNTLPWT (SEQ ID No.: 26), HCDR1: RYWML (SEQ ID No.: 27), HCDR2: EINPRNDRTNYNEKFKT (SEQ ID No.: 28), i HCDR3: GGGYAMDY (SEQ ID No.: 29), i gdje se navedena vežuća molekula veže na L1 s afinitetom (KD) od najmanje 10–10 M, ili (ii) karakteristično da njezina područja koja određuju komplementarnost (CDRs) imaju sljedeće sljedove: LCDR1: QDISNY (SEQ ID No.: 30), LCDR2: YTS, LCDR3: QQGNTLPWT (SEQ ID No.: 31), HCDR1: GYTFTRYW (SEQ ID No.: 32), HCDR2: INPRNDRT (SEQ ID No.: 33), i HCDR3: ALGGGYAMDY (SEQ ID No.: 34), i gdje se navedena vežuća molekula veže na L1 s afinitetom (KD) od najmanje 10–10 M.
2. Vežuća molekula koja se može vezati na L1 u skladu s patentnim zahtjevom 1, naznačena time što se vežuća molekula veže na L1 s afinitetom (KD) od najmanje 10–11 M.
3. Vežuća molekula koja se može vezati na L1 u skladu s patentnim zahtjevom 1 ili 2, naznačena time što je vezana na aktivnu tvar, po mogućnosti toksin, citokin, nanočesticu ili radionuklid.
4. Vežuća molekula koja se može vezati na L1 u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je namijenjena upotrebi u postupku liječenja tumorogene bolesti.
5. Vežuća molekula koja se može vezati na L1 u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je namijenjena upotrebi u postupku sensibiliziranja tumorskih stanica kod pacijenta radi liječenja kemoterapijskom lijekom ili radioterapijom.
6. Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 5, naznačena time što su stanice u najmanju ruku djelomično otporne na liječenje navedenim kemoterapijskim lijekom ili na radioterapiju.
7. Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 5 ili 6, naznačena time što se nakon sensibiliziranja vežućom molekulom pacijent dodatno liječi navedenim kemoterapijskim lijekom ili radioterapijom.
8. Vežuća molekula koja se može vezati na L1, naznačena time što je namijenjena upotrebi u skladu s patentnim zahtjevom 4, kod pacijenta prethodno liječenog kemoterapijskom lijekom ili radioterapijom.
9. Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 8, naznačena time što je pacijent u najmanju ruku djelomično otporan na liječenje navedenim kemoterapijskim lijekom ili radioterapijom.
10. Vežuća molekula koja se može vezati na L1, naznačena time što je (i) namijenjena upotrebi u skladu s patentnim zahtjevom 4, kod pacijenta koji je u najmanju ruku djelomično otporan na liječenje danim kemoterapijskim lijekom ili radioterapijom, ili (ii) namijenjena upotrebi u skladu s patentnim zahtjevom 4, gdje se vežuću molekulu primjenjuje u kombinaciji s kemoterapijskom lijekom ili radioterapijom.
11. Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 10, točka (ii), naznačena time što se kemoterapijski lijek ili radioterapija primjenjuje prije vežuće molekule.
12. Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 4 do 11, naznačena time što tumorske stanice ili tumorogena bolest su tipa koji se bira iz skupine koju čine astrocitom, oligodendrogliom, meningiom, neurofibrom, glioblastom, ependimom, Schwannom, neurofibrosarkom, meduloblastom, melanom, rak gušterače, karcinom prostate, rak glave i vrata, rak dojke, rak pluća, rak jajnika, rak endometrija, rak bubrega, neuroblastomi, karcinomi pločastih stanica, hepatom, rak debelog crijeva i mezoteliom i epidermoidni karcinom, ili, što su tumorske stanice iz tumora epitela ili što je tumorogena bolest tumor epitela.
13. Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s patentnim zahtjevom 12, naznačena time što je tumor epitela rak gušterače, rak debelog crijeva, rak jajnika ili rak endometrija.
14. Vežuća molekula koja se može vezati na L1, namijenjena upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 do 13, naznačena time što je kemoterapijski lijek sredstvo koje oštećuje DNA, koje se po mogućnosti bira iz skupine koju čine aktinomicin-D, mitomicin C, cisplatin, doksorubicin, etopozid, verapamil, podofilotoksin, 5-FU, taksani, po mogućnosti paklitaksel i karboplatin, ili, što se radioterapiju bira iz skupine koju čine rendgensko zračenje, UV-zračenje, γ-zračenje, α- ili β-zračenje, te mikrovalovi.
15. Farmaceutski pripravak, naznačen time što sadrži vežuću molekulu koja se može vezati na L1 u skladu s bilo kojim od patentnih zahtjeva 1 do 3.
16. Upotreba vežuće molekule koja se može vezati na L1 u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što je vežuća molekula namijenjena određivanju razine proteina L1 u tjelesnim tkivima ili tekućinama in vitro.
HRP20180192TT 2007-06-15 2018-02-01 Liječenje tumora specifičnim protutijelom protiv l1 HRP20180192T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94435907P 2007-06-15 2007-06-15
EP13000027.6A EP2631248B9 (en) 2007-06-15 2008-06-13 Treatment of tumors using specific anti-L1 antibody

Publications (1)

Publication Number Publication Date
HRP20180192T1 true HRP20180192T1 (hr) 2018-04-06

Family

ID=39862994

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20150007TT HRP20150007T8 (hr) 2007-06-15 2008-06-13 Lijeäśenje tumora pomoä†u specifiäśnog anti-l1 protutijela
HRP20180192TT HRP20180192T1 (hr) 2007-06-15 2018-02-01 Liječenje tumora specifičnim protutijelom protiv l1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20150007TT HRP20150007T8 (hr) 2007-06-15 2008-06-13 Lijeäśenje tumora pomoä†u specifiäśnog anti-l1 protutijela

Country Status (16)

Country Link
US (3) US8138313B2 (hr)
EP (2) EP2631248B9 (hr)
JP (2) JP5921066B2 (hr)
CA (2) CA2958672A1 (hr)
CY (2) CY1115960T1 (hr)
DK (2) DK2631248T3 (hr)
ES (2) ES2528167T3 (hr)
HR (2) HRP20150007T8 (hr)
HU (1) HUE036490T2 (hr)
LT (1) LT2631248T (hr)
NO (1) NO2631248T3 (hr)
PL (2) PL2170956T3 (hr)
PT (2) PT2631248T (hr)
SI (2) SI2631248T1 (hr)
TW (1) TWI478939B (hr)
WO (1) WO2008151819A2 (hr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
KR20100060351A (ko) * 2008-11-27 2010-06-07 한국생명공학연구원 Ｌ１ｃａｍ의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
WO2012058627A2 (en) * 2010-10-29 2012-05-03 Miqin Zhang Pre-targeted nanoparticle system and method for labeling biological particles
WO2014077648A1 (ko) 2012-11-16 2014-05-22 강원대학교산학협력단 인간 및 마우스 ｌ１ｃａｍ 단백질에 특이적으로 결합하는 항체 및 이의 용도
EP3200822B1 (en) * 2014-09-30 2021-04-14 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Binding molecules, especially antibodies, binding to l1cam (cd171)
KR20190036553A (ko) 2016-08-02 2019-04-04 메모리얼 슬로안 케터링 캔서 센터 전이성 암의 치료 및 전이성 질환에 대한 모델 시스템
EP3720882A4 (en) 2017-12-05 2021-10-27 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center T-CELLS WITH TWO DIFFERENT CHIMERIC ANTIGEN RECEPTORS AND THEIR USE
CN110540590B (zh) 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
WO2020003210A1 (en) 2018-06-29 2020-01-02 Kangwon National University University-Industry Cooperation Foundation Anti-l1cam antibodies and uses thereof
EP3868783A4 (en) 2018-10-19 2022-01-19 Cartexell Inc. ANTI-L1CAM ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND CHIMERIC ANTIGEN RECEPTOR THEREOF
WO2020243616A1 (en) * 2019-05-31 2020-12-03 Seattle Children's Hospital D/B/A Seattle Children's Research Institute E-cadherin activating antibodies and uses thereof
CA3262904A1 (en) 2022-09-21 2024-03-28 Elthera Ag NEW BINDING MOLECULES THAT BIND TO L1CAM
EP4615580A1 (en) * 2022-11-09 2025-09-17 CIS Biopharma AG Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
CN121941710A (zh) 2023-09-27 2026-04-28 艾尔瑟拉股份有限公司 用于治疗血液恶性肿瘤疾病的l1cam结合分子

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) * 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2091824T3 (es) 1989-04-21 1996-11-16 Us Health Proteina recombinante de fusion toxina anticuerpo.
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
IE911922A1 (en) 1990-06-07 1991-12-18 Scripps Clinic Res Apo ai polypeptides, diagnostic methods and systems for¹quantifying apo ai, and therapeutic methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) * 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
WO1993016177A1 (en) * 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
AU4953693A (en) 1992-08-25 1994-03-15 Medac Gesellschaft Fur Klinische Spezialpraparate Mbh Antibody/radioisotope conjugate for tumor diagnosis and/or therapy
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
US5837283A (en) 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1172654B1 (en) 2000-07-10 2007-10-31 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors
EP1293514B1 (en) 2001-09-14 2006-11-29 Affimed Therapeutics AG Multimeric single chain tandem Fv-antibodies
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
KR100470535B1 (ko) 2002-06-27 2005-02-22 재단법인서울대학교산학협력재단 유피에이 항체 부착 이뮤노리포좀
US20040115206A1 (en) * 2002-10-24 2004-06-17 Thomas Primiano Antibody-mediated induction of tumor cell death
US20040202666A1 (en) 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
GB0306618D0 (en) 2003-03-22 2003-04-30 Univ Newcastle Antibody
EP1623995A1 (en) 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
EP1928912A4 (en) 2005-09-07 2010-02-24 Medimmune Inc EPH ANTI-RECEPTOR ANTIBODIES CONJUGATED TO TOXINS
WO2007114550A1 (en) * 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
CA2661669C (en) * 2006-08-23 2017-02-14 Korea Research Institute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangniocarcinoma
AU2007221863A1 (en) 2006-10-16 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offenftlichen Rechts Treatment of chemotherapy -or radiothereapy-resistant tumors

Also Published As

Publication number Publication date
JP5921066B2 (ja) 2016-05-24
TW200918556A (en) 2009-05-01
EP2631248B9 (en) 2018-05-23
JP6042395B2 (ja) 2016-12-14
US8580258B2 (en) 2013-11-12
HUE036490T2 (hu) 2018-07-30
US8138313B2 (en) 2012-03-20
PL2170956T3 (pl) 2015-04-30
HRP20150007T1 (hr) 2015-03-13
US20090162355A1 (en) 2009-06-25
TWI478939B (zh) 2015-04-01
DK2170956T3 (en) 2015-02-02
EP2631248A2 (en) 2013-08-28
DK2631248T3 (en) 2018-02-12
EP2631248B1 (en) 2017-11-15
EP2170956B1 (en) 2014-10-22
LT2631248T (lt) 2018-04-25
SI2631248T1 (en) 2018-04-30
CY1115960T1 (el) 2017-01-25
CA2691075C (en) 2017-04-11
HRP20150007T8 (hr) 2015-08-14
CA2691075A1 (en) 2008-12-18
PT2170956E (pt) 2015-02-05
JP2015042651A (ja) 2015-03-05
EP2631248A3 (en) 2013-10-23
JP2010529970A (ja) 2010-09-02
WO2008151819A2 (en) 2008-12-18
CA2958672A1 (en) 2008-12-18
ES2528167T3 (es) 2015-02-04
ES2658342T3 (es) 2018-03-09
NO2631248T3 (hr) 2018-04-14
US20120258039A1 (en) 2012-10-11
US20140120117A1 (en) 2014-05-01
ES2658342T9 (es) 2018-06-06
PT2631248T (pt) 2018-02-15
WO2008151819A3 (en) 2009-04-09
US9260521B2 (en) 2016-02-16
SI2170956T1 (sl) 2015-02-27
EP2170956A2 (en) 2010-04-07
CY1119890T1 (el) 2018-06-27
PL2631248T3 (pl) 2018-06-29

Similar Documents

Publication Publication Date Title
HRP20180192T1 (hr) Liječenje tumora specifičnim protutijelom protiv l1
Ludwig et al. Monoclonal antibody therapeutics and apoptosis
Christiansen et al. Biological impediments to monoclonal antibody–based cancer immunotherapy
A. Baudino Targeted cancer therapy: the next generation of cancer treatment
Milenic et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease
JP2020529863A5 (hr)
JP2018536632A5 (ja) Ｂ７‐ｈ３に特異的に結合する分子及びｐｄ‐１に特異的に結合する分子
JP2020502271A5 (hr)
JP2022058802A5 (hr)
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2022533418A5 (hr)
CN112111008A (zh) 抗cd73抗体及其应用
ME02377B (me) Anti-igf antitijela
JP2013512920A5 (hr)
JP2019535731A5 (hr)
WO2019236684A1 (en) Antigen binding constructs to cd4
RU2016122041A (ru) Новые анти-клаудин антитела и способы их применения
JP2006507013A5 (hr)
JP2020522280A5 (hr)
JP2013511288A5 (hr)
Dou et al. ScFv‐decorated PEG‐PLA‐based nanoparticles for enhanced siRNA delivery to Her2+ breast cancer
JP2020522281A5 (hr)
IL276675B2 (en) Anti-PD-1 antibodies and uses thereof
Trail et al. Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96-doxorubicin
CA3070610A1 (en) Methods and compositions for targeting disease related cell surface receptors using radiolabeled and/or cytotoxin labelled antibodies